Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
323 Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
